Showing results (11-20 of 23) with videos related to
Sort By:
Pageof 3
Neurology|February 1, 1993
Primary T-cell lymphoma of the brainstemM P McCue, A W Sandrock, J M Lee, et al.Science (New York, N.Y.)|April 25, 1997
Maintenance of acetylcholine receptor number by neuregulins at the neuromuscular junction in vivoA W Sandrock, S E Dryer, K M Rosen, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|October 23, 2010
Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patientsR A Rudick, L Kappos, R Kinkel, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|December 6, 2005
Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patientsR A Rudick, G R Cutter, M Baier, et al.Neurology|November 27, 2002
A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MSM Clanet, E W Radue, L Kappos, et al.The New England Journal of Medicine|September 28, 2000
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study GroupL D Jacobs, R W Beck, J H Simon, et al.Neurology|March 4, 2009
GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled studyA D Goodman, H Rossman, A Bar-Or, et al.Neurology|September 11, 2002
Benefit of interferon beta-1a on MSFC progression in secondary progressive MSJ A Cohen, G R Cutter, J S Fischer, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2009
Assessing disability progression with the Multiple Sclerosis Functional CompositeR A Rudick, C H Polman, J A Cohen, et al.Archives of Neurology|June 19, 2001
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trialJ A Cohen, G R Cutter, J S Fischer, et al.Pageof 3